Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 3Lymphoma 3Lymphoma, Follicular 2Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

immunotoxin HA22 3Cyclophosphamide 2trametinib 1polatuzumab vedotin 1pembrolizumab 1ontuxizumab 1ibrutinib 1fludarabine 1dabrafenib 1brexucabtagene autoleucel 1acalabrutinib 1Trazodone 1Rituximab 1Prednisone 1PLX8394 1Lenalidomide 1HA 22 1Fentanyl 1Doxorubicin 1AGS67E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Hairy Cell × polatuzumab vedotin × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡